Changeflow GovPing Healthcare EPA Draft CCL 6 Includes Microplastics and Phar...
Priority review Consultation Added Draft

EPA Draft CCL 6 Includes Microplastics and Pharmaceuticals for Drinking Water Regulation

Favicon for www.jdsupra.com JD Supra Healthcare
Published April 2nd, 2026
Detected April 6th, 2026
Email

Summary

The EPA announced the draft Sixth Contaminant Candidate List (CCL 6) under the Safe Drinking Water Act on April 2, 2026. For the first time, microplastics and pharmaceuticals have been designated as potential contaminants, alongside PFAS (as a class), disinfection byproducts, 75 chemicals, and 9 microbes. The draft is open for public comment until June 1, 2026. The CCL process identifies emerging contaminants for research but does not itself impose regulatory requirements.

What changed

The EPA released draft CCL 6 on April 2, 2026, marking the first inclusion of microplastics and pharmaceuticals as potential drinking water contaminants under the Safe Drinking Water Act. The list also includes PFAS (as a class using the TSCA Section 8(a)(7) definition, which notably encompasses fluoropolymers), disinfection byproducts, 75 chemicals, and 9 microbes. Under SDWA Section 1412(b)(1)(B)(i), CCLs must be published every five years and serve as the first step toward potential Maximum Contaminant Level regulations.

Public water systems and affected industries should submit comments by June 1, 2026. Although the CCL process does not impose immediate obligations, entities should anticipate future monitoring requirements similar to UCMR 5 (which required sampling for 29 PFAS chemicals). Companies in sectors using fluoropolymers or discharging pharmaceuticals into water systems should review the broad definitions and prepare for potential regulatory action on specific contaminants that may be selected for MCLs.

What to do next

  1. Submit comments on draft CCL 6 by June 1, 2026
  2. Review PFAS definitions (including fluoropolymers under TSCA 8(a)(7)) for applicability to your operations
  3. Monitor for future UCMR sampling requirements for listed contaminants

Source document (simplified)

April 6, 2026

EPA Takes Steps to Regulate Microplastics, PFAS and Pharmaceuticals under the Safe Drinking Water Act

Jason Drogin Atwood, Reza Zarghamee Pillsbury - PFAS Observer + Follow Contact LinkedIn Facebook X Send Embed

The Safe Drinking Water Act (SDWA) is the primary federal law that protects drinking water quality and authorizes the EPA to promulgate regulations to limit harmful contaminants in public water systems. Under § 1412(b)(1)(B)(i) of the SDWA, the U.S. Environmental Protection Agency (EPA) must publish a Contaminant Candidate List (CCL) every five years identifying emerging contaminants that are not yet subject to a Maximum Contaminant Level (MCL) but that may pose a public health risk. CCLs are the first step in the SDWA regulatory process and are used to drive research into the listed contaminants to better understand health impacts, occurrence data, and risk levels. The CCL process is used to inform future regulatory action but does not impose any regulatory requirements in itself.

On April 2, EPA announced the release of the draft Sixth CCL (CCL 6) marking the first time that microplastics and pharmaceuticals have been designated as potential contaminants for regulation under the SDWA. The CCL 6 also lists, as a class, per- and polyfluoroalkyl substances (PFAS) and disinfection byproducts, as well as 75 chemicals and nine microbes.

  • Microplastics are tiny plastic particles measuring less than five millimeters in size that are ubiquitous in the environment and easily ingested by humans. Because this is the first time that microplastics have been included on the CCL, there are still significant data gaps and more investigation is necessary to determine detection methods, potential sources, and impacts on human health.
  • PFAS have been included on CCL lists as far back as 2009. The latest SDWA Unregulated Contaminant Monitoring Rule (UCMR 5) required regulated public water systems to sample for 29 PFAS chemicals. Notably, CCL 6 defines PFAS broadly, using the definition that EPA has developed for, among other things, the one-time PFAS Reporting Rule under Section 8(a)(7) of the Toxic Substances Control Act, 15 U.S.C. § 2601, et seq. This definition is notably controversial, as it includes fluoropolymers, which are widely used in commercial and industrial applications and do not present the same concerns of persistence, bioaccumulation, and toxicity as certain other types of PFAS (for example, long-chain alkyl acid PFAS). It remains to be seen which specific PFAS are selected for inclusion on the next UCMR list or for MCLs (similar to those finalized in 2024 for PFOA and PFOS).
  • The CCL employs a broad definition of pharmaceuticals, which covers any substance that meets the definition of a “drug” under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 321).
  • Disinfection byproducts (DBP) are formed when disinfectants used for antimicrobial treatment in drinking water react with organic or inorganic materials. The EPA has listed 27 unregulated DBPs, 23 of which were previously listed on CCL 5. EPA is seeking comments on the draft CCL 6 as well as on the process used to select the contaminants. Comments must be received on or before June 01, 2026.

[View source.]

Send Print Report

Related Posts

Latest Posts

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.

©
Pillsbury - PFAS Observer

Written by:

Pillsbury - PFAS Observer Contact + Follow Jason Drogin Atwood + Follow Reza Zarghamee + Follow more less

PUBLISH YOUR CONTENT ON JD SUPRA

  • ✔ Increased readership
  • ✔ Actionable analytics
  • ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Published In:

Comment Period + Follow Contamination + Follow Environmental Policies + Follow Environmental Protection Agency (EPA) + Follow PFAS + Follow Pharmaceutical Industry + Follow Plastics + Follow Prescription Drugs + Follow Proposed Rules + Follow Public Health + Follow Regulatory Authority + Follow Safe Drinking Water Act + Follow Toxic Chemicals + Follow Water Pollution + Follow Water Quality + Follow Administrative Agency + Follow Environmental + Follow Health + Follow more less

Pillsbury - PFAS Observer on:

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Sign Up Log in ** By using the service, you signify your acceptance of JD Supra's Privacy Policy.* - hide - hide

Named provisions

CCL 6 Draft List Microplastics Designation Pharmaceuticals Designation PFAS Class Definition Disinfection Byproducts

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPA
Published
April 2nd, 2026
Comment period closes
June 1st, 2026 (55 days)
Instrument
Consultation
Legal weight
Non-binding
Stage
Draft
Change scope
Substantive

Who this affects

Applies to
Government agencies Healthcare providers Manufacturers
Industry sector
2213 Water & Wastewater 3241 Chemical Manufacturing 6211 Healthcare Providers
Activity scope
Drinking Water Monitoring Contaminant Reporting Public Water System Operations
Geographic scope
United States US

Taxonomy

Primary area
Environmental Protection
Operational domain
Environmental Compliance
Topics
Water Quality Public Health Chemical Safety

Get Healthcare alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when JD Supra Healthcare publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.